FG
KIN

Formula Growth’s Kindred Biosciences, Inc. KIN Stock Holding History

Formula Growth’s Portfolio KIN Stock Details KIN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-90,000
Closed -$360K – 174
2020
Q1 		$360K Buy
90,000
+20,000
+29% +$170K 0.07% 132
2019
Q4 		$594K Hold
70,000
– – 0.07% 133
2019
Q3 		$480K Hold
70,000
– – 0.07% 140
2019
Q2 		$583K Hold
70,000
– – 0.08% 142
2019
Q1 		$642K Hold
70,000
– – 0.09% 134
2018
Q4 		$767K Buy
+70,000
New +$882K 0.13% 122

Other funds holding KIN

PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Formula Growth's KIN Position: Q2 2020 in Review

Formula Growth sold out of Kindred Biosciences, Inc. (KIN) in Q2 2020, closing a stake of 90,000 shares — an estimated $360K sold.

Formula Growth first reported a position in KIN in Q4 2018 and held it in 6 quarters. The position peaked at $767K in Q4 2018. 83 funds tracked by Wall St. Rank hold KIN as of Q2 2020.

  • Formula Growth reported no remaining Kindred Biosciences, Inc. position as of Q2 2020 after selling out during the quarter.
  • Formula Growth sold 90,000 Kindred Biosciences, Inc. shares in Q2 2020, an estimated $360K.
  • Formula Growth first reported a position in Kindred Biosciences, Inc. in Q4 2018 and held it in 6 quarters.
  • Formula Growth's Kindred Biosciences, Inc. position peaked at $767K in Q4 2018.
  • 83 funds tracked by Wall St. Rank held Kindred Biosciences, Inc. as of Q2 2020.

Based on Formula Growth's 13F filing for Q2 2020, filed 13 Aug 2020.